Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GENE-TRAK Systems was a biotechnology company specializing in the development of DNA probe-based diagnostic tests for food safety and clinical microbiology. The company's primary focus was the rapid detection of foodborne pathogens, including Salmonella, Listeria, and E. coli, using proprietary molecular hybridization technology. By targeting ribosomal RNA, GENE-TRAK's assays provided high sensitivity and specificity, significantly shortening the time-to-result compared to conventional microbiological culture techniques. The company was a leader in the transition from traditional methods to molecular diagnostics in the food industry. Originally formed as a joint venture involving Integrated Genetics and Amoco, it eventually became a part of Vysis before being acquired by Neogen Corporation in 2001.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GENE-TRAK Systems.